PURPOSE: This study evaluated the incidence of @entity2213 -associated @entity1910 , the interventional outcomes of severe @entity1910 , and impact of severe @entity1910 on the outcomes of @entity2213 treatment in @entity674 ( @entity674 ) @entity1 . MATERIALS AND METHODS: A total of 620 @entity1 were administered adjuvant or palliative @entity2213 for @entity674 at Asan Medical Center between January 2000 and July 2012. This analysis focused on a group of 42 @entity1 who developed a severe @entity1910 requiring major interventions, defined as dose interruption or reduction of @entity2213 or systemic @entity479 use. RESULTS: Of the 620 @entity1 treated with @entity2213 , 148 @entity1 (23.9%) developed an @entity2213 -associated @entity1910 ; 42 @entity1 (6.8%) developed a severe @entity1910 requiring major intervention. Of these, 28 @entity1 (66.8%) successfully continued @entity2213 with interventions. Serial blood eosinophil levels during @entity2213 treatment were associated with @entity1910 and severity. A significant association was observed between successful intervention and blood eosinophil level at the time of intervention initiation. In metastatic settings, @entity1 with severe @entity1910 requiring major interventions tended to show poorer progression-free survival than @entity1 who did not require major intervention and @entity1 with no @entity1910 , although this finding was not statistically significant (p=0.326). CONCLUSION: By aggressive treatment of severe @entity1910 through modification of @entity2213 dose or use of systemic @entity479 , the majority of @entity1 can continue on @entity2213 . In particular, @entity2213 dose intensity can be maintained with use of systemic @entity479 . Measuring the blood eosinophil levels may be helpful in guiding the management plan for @entity1910 regarding the intensity and duration of interventions.

Severe @entity2213 -Associated Skin Rash in @entity674 XXXX : Management and Clinical Implications.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['rash', 'skin rash'] @entity674 :: ('MESH:D046152', 'Disease') :: ['gastrointestinal stromal tumor', 'GIST'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib'] @entity479 :: ('D013256', 'Chemical') :: ['steroid']
@entity1 :: (9606,Species) :: ['Patients']
